Volume Comes Back Early: A 4% Organic Quarter Trips Our Upgrade Trigger, While a Bigger Oil Bill and a 23x Multiple Cap PG at Hold
Key Takeaways
- Volume came back sooner than we expected. Organic sales rose 4.0% on 2.4 points of volume, every one of the ten product categories and all six regions grew, and North America swung from a 1% decline in the June quarter to +3% on 3 points of volume. Share breadth recovered to 29 of the top 50 category-country combinations, from 23 in Q4.
- Management's own cadence puts the structural rate nearer 3% than 4%. It guides the first half to about 3%, which implies a December quarter near 2% against a flat comparison, citing European pre-shipments, a fuel-squeezed consumer and base-period noise. Three percent is still a full point above the 2% structural rate claimed for the back half of fiscal 2026, and that point is what changes our rating.
- The EPS beat is mostly timing, and the cost bill grew. Core EPS of $2.00 cleared the ~$1.89 consensus and the July steer of "down 5% or more," but only part of the commodity wave reached cost of goods and a ~$90M tariff refund helped. The fiscal 2027 headwind rose to $0.79 a share from $0.56 at a $100 Brent assumption that spot crude has already passed, and the $6.89 to $7.11 EPS guide was held, not raised.
- The first portfolio move is an addition, not a pruning. The $3.9B all-cash Thorne supplements deal closed on October 1, lifts all-in sales guidance to 2% to 4%, and adds roughly $150M of after-tax interest before it contributes any disclosed profit.
- Rating: Upgrading to Hold from Underperform. Our July note committed to a return to Hold on evidence of 2%+ organic growth with the share metric improving, and this quarter delivered both. At 23.0x the unchanged $7.00 FY27 midpoint, against 20.9x when we downgraded, the stock has already priced the operating turn while the oil overhang is still growing, so we stop at Hold with fair value raised to $155 to $170.
PG financial model
Income Statement · Dollars in millions, except per share
| Income Statement | ||||||
|---|---|---|---|---|---|---|
| Actual | Estimate | |||||
| FY24 | FY25 | FY26 | FY27E | FY28E | FY29E | |
| Total Net Sales | $84,039.0 | $84,284.0 | $87,032.0 | $88,723.9 | $90,655.2 | $92,633.4 |
| Less: Cost of Products Sold | ($40,848.0) | ($41,164.0) | ($43,362.0) | ($44,525.0) | ($45,222.3) | ($46,038.8) |
| Gross Profit | $43,191.0 | $43,120.0 | $43,670.0 | $44,198.9 | $45,433.0 | $46,594.6 |
| Less: Selling, General and Administrative Expense | (23,305.0) | (22,669.0) | (23,922.0) | (23,695.9) | (24,121.0) | (24,733.1) |
| Less: Indefinite-Lived Intangible Asset Impairment | (1,341.0) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Operating Expenses | ($24,646.0) | ($22,669.0) | ($23,922.0) | ($23,695.9) | ($24,121.0) | ($24,733.1) |
| Operating Income | $18,545.0 | $20,451.0 | $19,748.0 | $20,503.0 | $21,312.0 | $21,861.5 |
| Less: Interest Expense | (925.0) | (907.0) | (877.0) | (1,050.1) | (1,050.1) | (1,051.5) |
| Interest Income | 473.0 | 469.0 | 430.0 | 398.4 | 458.6 | 520.4 |
| Other Non-Operating Income/(Expense), Net | 668.0 | 154.0 | 1,076.0 | 876.4 | 895.5 | 917.1 |
| Rounding Residual | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Earnings Before Income Taxes | $18,761.0 | $20,167.0 | $20,377.0 | $20,727.7 | $21,616.0 | $22,247.5 |
| Less: Income Taxes | ($3,787.0) | ($4,102.0) | ($4,233.0) | ($4,311.4) | ($4,496.1) | ($4,627.5) |
| Net Earnings | $14,974.0 | $16,065.0 | $16,144.0 | $16,416.3 | $17,119.9 | $17,620.0 |
| Less: Net Earnings Attributable to Noncontrolling Interests | (95.0) | (91.0) | (98.0) | (98.5) | (102.7) | (105.7) |
| Net Earnings Attributable to Procter & Gamble | $14,879.0 | $15,974.0 | $16,046.0 | $16,317.8 | $17,017.2 | $17,514.3 |
| Less: Preferred Dividends | (284.0) | (291.0) | (292.0) | (281.1) | (273.3) | (268.3) |
| Net Earnings Available to Common Shareholders | $14,595.0 | $15,683.0 | $15,754.0 | $16,036.7 | $16,743.9 | $17,246.0 |
| Ratios & Assumptions | ||||||
| YoY Total Net Sales Growth | 2.5% | 0.3% | 3.3% | 1.9% | 2.2% | 2.2% |
| Gross Margin | 51.4% | 51.2% | 50.2% | 49.8% | 50.1% | 50.3% |
| Operating Margin | 22.1% | 24.3% | 22.7% | 23.1% | 23.5% | 23.6% |
| Net Margin (consolidated) | 17.8% | 19.1% | 18.5% | 18.5% | 18.9% | 19.0% |
| Net Margin (attributable to P&G) | 17.7% | 19.0% | 18.4% | 18.4% | 18.8% | 18.9% |
The full workbook adds 20 historical and 8 projected quarters, plus KPI Drivers · Balance Sheet · Cash Flow Statement · Operating Segments · Pro-Forma / Non-GAAP Reconciliation — every subtotal a live formula, every projection traced to a driver.
Results vs. Consensus
This is the print the bear case said would not come in fiscal 2027's first half. Organic sales beat the Street by about two points, every segment beat its organic estimate, volume did most of the work, and core EPS came in eleven cents ahead of both consensus and the company's own July steer. The caveats are on the cost side, not the demand side: core gross margin fell 150 bps, the commodity wave had only partly reached the P&L, and management used the beat to absorb a bigger cost bill rather than to lift the earnings guide.
Q1 FY2027 scorecard
| Metric | Actual | Consensus | Beat/Miss | Magnitude |
|---|---|---|---|---|
| Net sales | $23.276B | ~$22.8B | Beat | +2.1% |
| Organic sales growth | +4.0% | ~+2% | Beat | ~2 pts |
| Organic volume | +2.4% | n/a | Strong | majority of growth |
| Core EPS | $2.00 | $1.89 | Beat | +$0.11 (+5.8%) |
| Core EPS growth (YoY) | +1% | n/a | Above July steer | vs. company steer of "down 5% or more" |
| GAAP diluted EPS | $1.97 | n/a | Up YoY | +1% |
| Core gross margin | 50.0% | n/a | Down YoY | (150) bps |
| Core operating margin | 25.9% | n/a | Down YoY | (80) bps |
| Free cash flow productivity | 93% | n/a | Strong | vs. 85% to 90% FY guide |
Year-over-year comparison
| Metric | Q1 FY27 | Q1 FY26 | Change |
|---|---|---|---|
| Net sales ($M) | 23,276 | 22,386 | +4% |
| Cost of products sold ($M) | 11,678 | 10,887 | +7% |
| Gross profit ($M) | 11,598 | 11,499 | +1% |
| SG&A ($M) | 5,661 | 5,643 | 0% |
| Operating income ($M) | 5,937 | 5,856 | +1% |
| Interest expense ($M) | 223 | 197 | +13% |
| Other non-operating income, net ($M) | 207 | 268 | (23)% |
| Net earnings attributable to P&G ($M) | 4,731 | 4,750 | 0% |
| GAAP diluted EPS | $1.97 | $1.95 | +1% |
| Core EPS | $2.00 | $1.99 | +1% |
| Currency-neutral core EPS | $1.99 | $1.99 | 0% |
| Gross margin | 49.8% | 51.4% | (160) bps |
| Core gross margin | 50.0% | 51.5% | (150) bps |
| Core SG&A (% of sales) | 24.1% | 24.9% | (80) bps |
| Core operating margin | 25.9% | 26.7% | (80) bps |
| Effective tax rate (GAAP) | 21.0% | 20.8% | +20 bps |
| Diluted weighted average shares (M) | 2,407.2 | 2,436.8 | (1.2)% |
Sequential comparison (vs. Q4 FY2026)
| Metric | Q4 FY26 | Q1 FY27 | Trend |
|---|---|---|---|
| Organic sales growth | 0% | +4.0% | accelerated 4 pts |
| Organic volume | 0% | +2.4% | turned positive |
| Core EPS growth (YoY) | (3)% | +1% | turned positive |
| Core gross margin change (YoY) | flat | (150) bps | commodity wave arriving |
| Core operating margin change (YoY) | (130) bps | (80) bps | less compression |
| North America organic | (1)% | +3% | swung positive |
| Greater China organic | +4% | +8% | accelerated |
| Categories growing organic sales | 6 of 10 (held or grew) | 10 of 10 | fully broad-based |
| Regions growing organic sales | 5 of 7 (held or grew) | 6 of 6 | fully broad-based (new structure) |
| Top-50 combinations holding or growing share | 23 | 29 | +6 |
| Top US customers where P&G holds or grows share | ~50% (H2 FY26) | >70% | improving |
The region count is not like-for-like: P&G reorganized its regional structure on July 1, combining Europe into a single region and creating an India, Middle East, Turkey and Africa cluster, so the seven regions of fiscal 2026 are now six. The direction of travel is unambiguous either way.
Quality of the beat. The top line is the real news and it is high quality. The earnings beat is mostly timing. Three observations:
- Volume-led and broad. 2.4 points of volume, 1.1 of mix and only 0.4 of price, with every category and region growing. The two segments most exposed to private label, Fabric & Home Care and Baby, Feminine & Family Care, posted negative pricing (0.3 and 1.2 points) and the strongest volumes in the portfolio (4.3 and 2.3 points). That is the value correction of the past two quarters converting to units.
- The commodity wave had only partly arrived. Management said Q1 carried a 5% earnings headwind from input costs, against 8% for the full year at a $100 Brent assumption. On our arithmetic, charging Q1 at the full-year rate would have cost roughly six cents. A second installment of the IEEPA tariff refund, about $90M, added roughly three cents more on our estimate (assuming that figure is pre-tax). Together those two items account for most of the eleven-cent beat.
- Buybacks did the last mile. Core net earnings attributable to P&G fell 0.9% to $4,808M; a 1.2% lower diluted share count turned that into +1% core EPS. Currency-neutral core EPS was flat.
Assessment: Revenue
Net sales of $23.276B grew 4.0%, and for once all of it was organic: foreign exchange and acquisitions each contributed nothing. Volume added 2.4 points, mix 1.1 and pricing 0.4. Every segment beat the Street's organic estimate, with the widest gaps in Grooming (4.5% against roughly 0.5%) and Baby, Feminine & Family Care (3.0% against a modest expected decline). P&G also began reporting sales growth to one decimal place this quarter, a small change that removes some of the rounding ambiguity that made the past year's 0%, 3% and 0% prints hard to read.
The comparison is fair, not easy: the year-ago quarter grew 2% organically, so the two-year stack is roughly 6%. The honest discount is to the timing items management itself flagged: about a point of pre-shipment in Europe ahead of promotional events, roughly three points of China growth from a competitor's disruption in diapers, and whatever share of North America's swing reflects retailers rebuilding the inventory they cut in June. Management's first-half guide of about 3% is the cleanest read of the underlying rate, and it is a point higher than the 2% structural run rate management described for the back half of fiscal 2026.
Assessment: Margins
Core gross margin fell 150 bps, a wider decline than Q3's 100 bps and a reversal of Q4's flat reading. The bridge is straightforward: 140 bps of higher commodity costs, 140 bps of product and packaging reinvestment, 50 bps of unfavorable mix and 10 bps of other items, partly offset by 120 bps of productivity, 50 bps from lower tariff costs and recognized recoveries, and 20 bps of pricing. At the segment level the pressure concentrated where the volume came from: Fabric & Home Care gross margin fell 290 bps and Baby, Feminine & Family Care fell 220 bps, while Health Care rose 200 bps and Grooming 60 bps on pricing, tariff recoveries and productivity.
What saved the operating line was overhead. Total SG&A dollars were unchanged at about $5.7B as higher marketing spend was offset by lower overhead, and core SG&A fell 80 bps as a share of sales (130 bps of productivity and 100 bps of sales leverage against 120 bps of reinvestment and 40 bps of other items, a bridge that sums to the 70 bps currency-neutral figure). Core operating margin therefore fell only 80 bps, against 130 bps in Q4 with a flat gross margin. Gross productivity inside operating margin was 250 bps. The restructuring is now visibly reaching the P&L, and the leverage that 4% organic growth produces is real. It is also arriving into the steepest part of the cost curve.
Assessment: EPS
Core EPS of $2.00 rose 1% and was flat currency-neutral, eleven cents above the roughly $1.89 consensus and the "down 5% or more" steer management gave in July. Core operating income rose 1.1% to $6,035M, but non-operating items took it back: core other non-operating income fell $66M to $209M, interest expense rose $26M, and the GAAP tax rate edged up 20 bps to 21.0%. GAAP diluted EPS of $1.97 carried three cents of incremental restructuring.
The quarter is 28.6% of the $7.00 full-year midpoint, which sounds comfortable until the phasing is applied. To reach the guide, the remaining nine months need $4.89 to $5.11 against $4.90 a year earlier, growth of roughly 0% to 4% while absorbing the larger share of a cost headwind that management says will be "materially higher" from Q2. The beat bought cushion; it did not change the shape of the year.
Segment Performance
The segment table reverses the defining fact of the June quarter. In Q4 every reportable segment's net earnings fell by double digits; this quarter three of five grew profit, and the two that did not were down 1% and 4%. Organic growth ranged from 2.7% in Health Care to 5.4% in Beauty.
Q1 FY2027 reportable segments
| Segment | Net sales ($M) | Net sales growth | Organic sales | Organic volume | Earnings before taxes ($M) | Net earnings ($M) | Net earnings growth | Pre-tax margin |
|---|---|---|---|---|---|---|---|---|
| Beauty | 4,410 | +6.4% | +5.4% | +2.2% | 1,139 | 868 | (1)% | 25.8% |
| Grooming | 1,889 | +4.0% | +4.5% | (0.4)% | 619 | 477 | +3% | 32.8% |
| Health Care | 3,318 | +3.1% | +2.7% | (2.9)% | 1,029 | 783 | +9% | 31.0% |
| Fabric & Home Care | 8,205 | +4.2% | +4.8% | +4.3% | 2,080 | 1,601 | +3% | 25.4% |
| Baby, Feminine & Family Care | 5,322 | +2.9% | +3.0% | +2.3% | 1,390 | 1,060 | (4)% | 26.1% |
| Corporate | 132 | n/a | n/a | n/a | (234) | (32) | n/a | n/a |
| Total P&G | 23,276 | +4.0% | +4.0% | +2.4% | 6,023 | 4,757 | (1)% | 25.9% |
Pre-tax margin is each segment's earnings before income taxes divided by its own net sales. The five segments plus Corporate sum exactly to the income-statement totals for net sales, earnings before taxes and net earnings.
Q1 FY2027 net sales drivers
| Segment | Volume | Foreign exchange | Price | Mix | Acquisitions & divestitures | Net sales |
|---|---|---|---|---|---|---|
| Beauty | 2.2% | 1.1% | 0.7% | 2.5% | 0.0% | 6.4% |
| Grooming | (0.4)% | (0.4)% | 3.5% | 1.5% | (0.1)% | 4.0% |
| Health Care | (2.9)% | 0.4% | 2.8% | 2.8% | (0.1)% | 3.1% |
| Fabric & Home Care | 4.3% | (0.6)% | (0.3)% | 0.8% | 0.0% | 4.2% |
| Baby, Feminine & Family Care | 2.3% | (0.1)% | (1.2)% | 1.8% | 0.0% | 2.9% |
| Total P&G | 2.4% | 0.0% | 0.4% | 1.1% | 0.0% | 4.0% |
Category organic growth and global value share
| Category | Organic sales | Value share change | Read |
|---|---|---|---|
| Fabric Care | Mid single digits | +0.4 pts | Volume gains in North America, Europe and Latin America |
| Home Care | Mid single digits | unchanged | North American distribution gains, European innovation |
| Baby Care | Mid single digits | +0.8 pts | Greater China up more than 40%; North America low single digits |
| Feminine Care | Low single digits | unchanged | North America and Greater China up high singles; Europe down |
| Family Care | Low single digits | (0.5) pts (North America) | Volume up, pricing down on merchandising investment |
| Hair Care | Mid single digits | unchanged | Innovation pricing in North America and Latin America |
| Skin Care | Mid single digits | (0.6) pts | SK-II mix; Greater China volume down on competition |
| Personal Care | Mid single digits | (0.4) pts | Europe up more than 20%; trade investment |
| Grooming | +4.5% | +0.2 pts | Innovation pricing in North America and IMETA |
| Oral Care | Low single digits | (0.6) pts | Premium mix; North American volume lost to competition |
| Personal Health Care | Low single digits | +0.5 pts | Pricing; volume down on a weak cough and cold season |
Share rose in four of the eleven reported categories, held in three and fell in four. The company describes global aggregate share as flat across every time period. That is a meaningful improvement in breadth from Q4, but it is not yet the broad share growth the reinvestment case requires, and the four decliners include two premium franchises, Skin Care and Oral Care.
Q1 FY2027 regional organic growth
| Region | Q1 organic sales | Read |
|---|---|---|
| Focus markets (aggregate) | +4% | From (1)% in Q4 |
| North America | +3% | Volume +3 points; US also +3%; over 70% of top US customers holding or growing share |
| Europe | +4% | All key markets growing, the UK up high single digits; about a point of pre-shipment |
| Greater China | +8% | Volume +5%; roughly 3 points from a competitor's issue in diapers |
| Enterprise markets (aggregate) | +5% | Now Latin America, Asia Pacific Enterprise and IMEA |
| Latin America | +4% | Mexico up double digits, Brazil up low single digits |
| India, Middle East, Turkey and Africa (IMEA) | +8% | New cluster from July 1 |
| Asia Pacific Enterprise | +2% | Still carrying deliberate market exits |
Fabric & Home Care
The largest segment, 35% of sales, delivered the quarter's best volume: organic sales rose 4.8% on 4.3 points of volume and 0.8 of mix, with pricing slightly negative. Fabric Care grew mid single digits on volume in North America, Europe and Latin America and gained 0.4 points of global share; Home Care grew mid single digits on North American distribution gains and European innovation, with share unchanged. Management put US and European Fabric Care growth at 4% and 5% respectively, with North American value share up 70 bps and European value share up 60 bps over the latest three months.
"Fabric Care specifically, you are right in The U.S. Fabric Care business is growing at 4%. So strong results. In Europe, we are growing 5%. And we are growing share in both regions."
— Andre Schulten, CFO
The cost of that growth shows up one line down. Segment gross margin fell 290 bps on commodities, product investment and mix, the steepest decline in the company. Net earnings still rose 3% on a 4.2% sales gain because lower marketing and overhead as a share of sales absorbed most of the gross-margin decline.
Assessment: This is the "stronger core" playbook working exactly as described in July: better product at the same price, Tide's upgraded liquid and the Gain and fabric-enhancer innovations taking volume and share in the two largest laundry markets. It is also the playbook's financial signature, a business winning on units while giving up nearly three points of gross margin. Laundry is resin- and energy-intensive, so this is the segment where the oil assumption matters most.
Baby, Feminine & Family Care
Last quarter's weakest segment grew organic sales 3.0% on 2.3 points of volume and 1.8 of mix, with 1.2 points of negative pricing. Baby Care grew mid single digits and gained 0.8 points of global share: Greater China rose more than 40% and IMETA low teens, while North America grew low single digits on lower pricing. Feminine Care grew low single digits on North American distribution gains. Family Care, predominantly a North American business, grew low single digits on volume but lost 0.5 points of North American share even with merchandising investment holding price down.
"Global baby care is up. Top line is growing 5%. Shares growing 80 bps. Baby Care in The U.S. is up 3% on sales, 7% on volume. And up both in volume share and value share."
— Andre Schulten, CFO
Net earnings fell 4% as gross margin dropped 220 bps on commodities and merchandising investment, partly offset by lower tariffs and overhead.
Assessment: The segment is doing what July's price-point correction was supposed to do: volume is back and US Baby Care is gaining share on 7% volume growth. The bill is margin, and it is unlikely to be repaid soon in Family Care, where input and energy costs are rising and management concedes it has "not yet seen the share turn." The premium-diaper trade-up (Pampers' new top tier, discussed below) is the part of this segment that could earn its way back to margin; the tissue and towel recovery is the part that will not.
Beauty
Beauty grew organic sales 5.4%, the fastest in the company, on 2.2 points of volume, 2.5 of mix and 0.7 of price. Hair Care, Personal Care and Skin Care each grew mid single digits: Hair Care on innovation pricing in North America and Latin America, Personal Care on Greater China and Europe volume (Europe up more than 20%), and Skin Care on SK-II mix and North American volume. Yet segment share fell 0.2 points, with Skin Care down 0.6 and Personal Care down 0.4, and net earnings slipped 1% as gross margin fell 90 bps and marketing rose.
"I will tell you our beauty team is not content with 5% growth. there is way more opportunity in that space that we need to capture."
— Andre Schulten, CFO
Assessment: Beauty is again the best demand story and the clearest share problem. A segment growing 5% while losing share in two of three categories is growing slower than its markets. Management's own language says the same thing. This is the segment where the Investor Day will need to show a plan rather than a growth rate.
Health Care
Health Care grew organic sales 2.7%, carried entirely by 2.8 points of price and 2.8 of mix against a 2.9-point volume decline, the only segment besides Grooming with lower volume. Personal Health Care grew low single digits on pricing and gained 0.5 points of share despite a weak cough and cold season; Oral Care grew low single digits on power brushes and premium paste but lost 0.6 points of share on North American competition and restructuring exits. Net earnings rose 9%, the best in the company, on a 200 bps gross-margin gain from pricing, tariff recoveries and productivity.
Assessment: The profit line is the strongest in the portfolio and the volume line is the weakest, which is the signature of a pricing-led quarter. Management said cough and cold incidence picked up in the latest weeks; if that holds, Personal Health Care volume should recover in the winter quarters. Thorne joins this segment from Q2, which will change its growth profile and complicate the organic comparison for a year.
Grooming
Grooming grew organic sales 4.5% on 3.5 points of innovation pricing and 1.5 of mix, with volume down 0.4 points as European gains were offset by Latin American distribution losses and IMETA exits. Global share rose 0.2 points, and net earnings grew 3% on a 60 bps gross-margin improvement.
Assessment: The single biggest beat against Street estimates and a clean demonstration of innovation pricing working: 3.5 points of price with only a fractional volume loss and a share gain. At 8% of sales it does not move the consolidated arithmetic, but it is the clearest evidence in the portfolio that P&G can still price where its products are differentiated, which matters for the pricing question discussed below.
Key Topics & Management Commentary
Overall Management Tone: Management was more confident than at any point in the past four quarters on the business it controls and deliberately restrained on everything it does not. The prepared remarks led with breadth rather than with adjusted versions of the number, a clear change from July, and the Q&A was spent talking analysts down rather than up: first-half organic of about 3%, no commitment to the EPS midpoint, and repeated warnings that the path "will not be a straight line." The least convincing stretch came on cost phasing, where management confirmed that the December quarter carries the full $100 oil cost and then declined to size it.
1. Volume leads a 4.0% quarter, and what is structural inside it
The headline is 4.0% organic, but the composition is the story. Volume did most of the work, 2.4 points against 0.4 of pricing and 1.1 of mix, the largest volume contribution since we began covering the stock. Every one of the ten product categories grew, six of them at mid single digits, and every region grew. As one line of questioning noted, the last time P&G combined volume above 2% with organic growth of 4% was fiscal 2022.
"Volume increased 2.4 points Pricing was up 0.4 points. And mix was up over 1 point for the quarter. A solid balance across top line drivers and with the majority of growth driven by volume."
— Andre Schulten, CFO
Management was equally explicit that 4% is not the run rate it is planning on. It guided the first half to about 3%, which implies a December quarter near 2% against a quarter a year ago that was flat. The stated reasons were a point of European pre-shipment ahead of promotional events, a consumer under fuel-price pressure, and base-period inventory swings. Our five-quarter view of the reported numbers, +2%, 0%, +3%, 0% and now +4.0%, explains why management is cautious about extrapolation: the past year has alternated rather than trended.
Assessment: We take management's 3% as the structural read, which is a full point better than the 2% it claimed for the back half of fiscal 2026 and at the bottom of the long-term algorithm's 3% to 5% range. That point is what has changed. The 4% headline flatters it, and the December quarter will very likely print below it; that is a known, guided deceleration, not a new disappointment.
2. North America swings from minus 1% to plus 3%
The company's largest and most profitable market delivered the biggest turn. North America grew 3% organically on 3 points of volume, the US market also grew 3%, and the share of P&G's top US retail customers where it held or grew share rose above 70%. Management restated its target of above 80% by the end of the calendar year.
"In North America, volume was up 3 points, driven by continued improvement in consumption across categories. We now have over 70% of our top U. S. Customers holding or growing share, up from less than 10% in the first half fiscal 2026, and 50% in the second half of last fiscal year."
— Andre Schulten, CFO
Part of the swing is mechanical. In Q4 North American consumption grew 2% while shipments fell 1%, a three-point gap management attributed to retailer destocking and the Prime Day calendar. Shipments matching or exceeding consumption this quarter would recover some of that, and management warned that a significant inventory shift in last year's March quarter will create a similar distortion in the coming March quarter.
Assessment: The two-quarter average for North America is roughly 1%, which is a fairer measure of the trend than either print alone. But the customer-level share metric is not distorted by inventory, and its path from under 10% to 50% to above 70% over three readings is the strongest single piece of evidence that the interventions are working in the US. If it reaches 80% by December, the bear case on US share loss is over.
3. Share breadth recovers to 29 of 50, with gaps in the premium franchises
P&G held or grew share in 29 of its top 50 category-country combinations fiscal year to date, up from 25 in the second half of fiscal 2026, 23 in Q4, and 26 for fiscal 2026 as a whole. Global aggregate share was flat across all time periods. Management described itself as "about 60% down the path" of fixing each combination.
"Global aggregate market share is flat versus prior year across all time periods. 29 of our top 50 category country combinations held or grew share fiscal year to date, up from 25 in the second half of last fiscal year also a reflection of the progress being made across the portfolio."
— Andre Schulten, CFO
The 10-Q's category detail is less uniform. Share rose in Baby Care (+0.8), Personal Health Care (+0.5), Fabric Care (+0.4) and Grooming (+0.2); it fell in Skin Care (-0.6), Oral Care (-0.6), Family Care (-0.5 in North America) and Personal Care (-0.4).
Assessment: Twenty-nine matches the fiscal 2025 full-year reading and is a decisive break from the eight-year low we flagged in July. The split between combinations that grew and those that merely held remains undisclosed for a second quarter. The share losers include two premium franchises, Skin Care and Oral Care, which tempers the read. The gains came both where P&G cut price (Baby Care) and where it raised price with innovation (Grooming, Personal Health Care), so the recovery does not depend on price investment alone.
4. Category growth is running ahead of the guide's assumption
July's organic guide was built on 2% global category growth, with the 2% midpoint requiring P&G to grow about half a point faster than its markets. Management now sees categories growing faster, led by the US.
"In aggregate, the consumer is resilient. We see 2% to 3%, 2.5% to 3% value growth across all categories globally. That is unchanged maybe a little bit better than what we saw and reported last quarter. We see improvements in The U. S. So we talked about 2% last quarter. We are running up to 3% now."
— Andre Schulten, CFO
Enterprise markets were described as growing 4% to 6%, perhaps 6% to 7% on the latest reading, and Europe as stable but muted at about 1%. Management also volunteered that North American category growth is now approaching 3% in value, and that it would like to think its own innovation is part of that acceleration.
Assessment: This is the quiet reason the 1% to 3% organic range now looks conservative. If categories grow 2.5% to 3% and P&G merely holds share, organic growth lands at or above the midpoint of the range after the 30 to 50 bps restructuring drag, before any share gain. Management's own first-half 3% and "slight acceleration" thereafter imply a full year above 3%. The range was not raised, which we read as deliberate caution on the consumer rather than doubt about the base case.
5. The cost bill rises to $0.79, on an oil price already out of date
The fiscal 2027 headwind grew by $0.23 a share in three months. The commodity component rose to about $1.4B after tax from $1.0B, on an effective Brent assumption raised to $100 from $90, and net interest doubled to about $300M after tax as roughly $150M of new interest arrives with the acquisition debt. Combined with $150M of lower non-operating income and $50M of foreign exchange, the drag is about $1.9B after tax, $0.79 a share or 11% of fiscal 2026 core EPS, against $0.56 or 8% in July.
"This estimate assumes an effective Brent crude oil price of $100 a barrel Due to the duration of higher oil prices, we now expect materially higher cost headwinds in Q2. And the second half of fiscal 2027."
— Andre Schulten, CFO
The $100 assumption was stale on the day it was issued. Management said crude was trading north of $110 that morning, and in response to a question on phasing said plainly that $113 oil means more cost in the second half than the guide carries.
Assessment: At the same $100 oil assumption management used in April, the estimate is now $1.4B rather than $1.0B, 40% larger: July added non-commodity supply-chain inflation, and this quarter added the duration of high oil prices. In July a $10 lower crude assumption produced no relief; this quarter a $10 higher one added $400M after tax, and the market is another $10 above that. The guide absorbed a $0.23 increase without moving, which is a genuine sign of operating strength, but the bear point on cost is not contained. It is growing, and the next quarter is the one where it lands in full.
6. Margins: overhead and productivity carry the quarter while the commodity wave is still arriving
Core operating margin fell 80 bps on a 150 bps gross-margin decline, cushioned by 80 bps of SG&A leverage. Management split the explanation between structural leverage, which it says is increasing, and two quarter-specific items: a partial commodity flow-through and a second installment of the IEEPA tariff refund.
"When we see growth around 4% and volume growth at or above 2%, we have always seen leverage. Think that leverage structurally is increasing. Number 1, on the cost of goods side, the level of productivity we are generating is increasing."
— Andre Schulten, CFO
The structural argument rests on three things: supply-chain automation lifting cost-of-goods productivity, the 15% reduction in non-manufacturing headcount now flowing through the P&L, and brand-building spend working harder, which management described as driving top-line growth "at flat spending." The 10-Q is more precise: marketing spending rose in dollars and fell only as a share of sales, offset by lower overhead. Productivity in the quarter was about $500M to $550M before tax, on a pace similar to fiscal 2026's $2.8B and weighted to the second half.
"In Q1, we only saw 5% headwind. Year over year. So that is a little bit of a onetime that will be correcting itself as we get towards the ongoing oil price impact through the P and L."
— Andre Schulten, CFO
Assessment: The overhead leverage is real and is the clearest evidence yet that the restructuring is paying: SG&A dollars were flat while sales grew 4%. The gross-margin line is the problem, and it is about to get worse. A quarter that carried a 5% input-cost headwind printed core gross margin down 150 bps; the full-year rate is 8% at $100 oil and higher at today's price. We expect core gross margin declines of around 200 bps in the December and March quarters.
7. Guidance held, not raised: 3% in the first half and no midpoint commitment
Every core guidance range was maintained: organic 1% to 3%, core EPS growth 0% to 3% ($6.89 to $7.11), free cash flow productivity 85% to 90%, and about $15B of cash returned. All-in sales growth moved up a point to 2% to 4% for Thorne, and the core tax rate moved to 20% to 21%. Management acknowledged that the year had started above its own organic range.
"We continue to expect sales growth of 1% to 3%, We started the year above this range, but we expect growth to be volatile quarter to quarter due to base periods dynamics."
— Andre Schulten, CFO
On the top line, management went further than the range, steering the first half to about 3% and the second half to slightly better, with the caveat that individual quarters will move around. On earnings it went less far: asked directly whether the midpoint was still achievable, it confirmed only the range.
Assessment: The asymmetry is the message. Management is signaling the top end of the organic range and declining to defend the middle of the earnings range. That is a consistent position given an oil price $10 to $13 above the guide's assumption, and it tells investors the year's upside lives in sales and its risk lives in costs. We model organic growth of about 3% and core EPS of $6.92, near the bottom of the earnings range.
8. Pricing comes back into the toolkit
The pricing language moved. In July management stressed that promotion was returning to pre-pandemic levels and that price-mix would stay positive, as it had in 20 of 21 years. This quarter it said outright that the industry is pricing up because costs of this size cannot be recovered any other way. The framework for offsetting the cost bill has three parts: record productivity, pricing with innovation, and time.
"The last point I leave you with at this level of commodity pressure, not a projection, just a fact, the industry generally is pricing up. Because there is no way to recover this level of commodity pressure without pricing, that is fact of the past, it does not have to hold true for the future."
— Andre Schulten, CFO
Management would not announce or quantify pricing, but noted that P&G prices with innovation and that innovation is generally timed to retailers' shelf resets, which points to the second half. It also described the balance between price, product, packaging and execution as "very fragile," and said the team would not jeopardize the top-line momentum to recover cost faster.
Assessment: This is the most important forward-looking change on the call. A volume-led recovery is exactly the condition under which a staples company can take price, and Grooming's 3.5 points of price with a share gain shows P&G can still do it where products are differentiated. The risk is the obvious one: the value corrections that rebuilt volume in Fabric Care, Baby Care and Family Care were price cuts in effect, and reversing them in the same year tests whether the new users stay.
9. Thorne: the first portfolio move is an addition
The question we raised in July, whether management would reshape the portfolio, has a first answer, and it is an acquisition rather than a divestment. P&G closed the $3.9B all-cash purchase of Thorne, a premium vitamins, minerals and supplements brand selling mainly in North America, on October 1. It joins the Personal Health Care operating segment, will be reported from the December quarter, and is described in the 10-Q as not material to the company.
"But at the core, job number 1 is to retain what made Thorne a successful brand."
— Andre Schulten, CFO
Management framed the integration as deliberately light: Thorne's team leads, with P&G supplying international expansion, supply-chain, ingredient-qualification and marketing support where needed, and expansion into other categories later. The financing is visible in the balance sheet, where cash rose to $15.4B at September 30 on new short-term borrowing, and in the guide, where roughly $150M of after-tax interest now sits in the headwind.
Assessment: Strategically coherent: a premium wellness brand with ambitious growth plans, in an adjacency to Personal Health Care. Financially, it carries roughly six cents a share of acquisition-related interest in fiscal 2027 before any disclosed profit contribution, and the 10-Q's "not material" means investors will get little visibility on whether it is earning its price. Revenue, growth and margin were deferred to the Investor Day.
10. Greater China grows 8%, with a competitor's stumble inside it
Greater China grew 8% organically on 5 points of volume, its sixth consecutive quarter of growth in a market management says is still growing below 1% in its categories. Baby Care, normally growing around 20% there, grew almost 50% this quarter as a competitor's disruption drove trial to Pampers.
"But, yes, we have benefited somewhat about 3 points. So if you take that out, China would still be growing at 5% that it has been growing so mid single digits."
— Andre Schulten, CFO
Outside diapers, SK-II grew in the low teens, Fabric Care 5% and Feminine Care 9%, while Olay remains in the middle of a reinvention and is not growing.
Assessment: Management deserves credit for quantifying the one-off rather than banking it. Ex the competitor effect, China is a steady mid-single-digit grower taking share in a flat market, which validates the go-to-market rebuild. The three points of windfall will not recur, and retaining the trial users is the open question for the next two quarters.
11. Premium trade-up as the growth model, and Family Care still waiting for its share turn
Management laid out a consistent premium thesis in Baby Care: fewer children per household means more spending per child, and superior premium propositions win. Pampers' new top-tier US diaper is projected to exceed $100M in its first year, US Baby Care volume grew 7%, the mid-tier upgrade has just launched, and wipes and Swaddlers innovation is still to come.
"We have fixed what I will call the hygiene factors, value versus close competition, and we are building on the trend that we see as the future growth engine for this category, which is less babies means more spending per baby."
— Andre Schulten, CFO
Family Care is the counterexample. It grew low single digits on volume but lost 0.5 points of North American share. The interventions, price-point corrections in the club channel and a relaunched Charmin and Bounty Essentials value line, have grown users without yet turning share.
"Family care is not yet back to share growth. Interventions we are making across price point corrections in the club channel, the launch of Charmin and Bounty Essentials, all of those pushing momentum in the right direction. But we have not yet seen the share turn."
— Andre Schulten, CFO
Assessment: The premium trade-up model is the margin-accretive half of the recovery and the value-tier work in Family Care is the margin-dilutive half. Management expects Family Care to return to share growth in the second half; that is a specific, checkable commitment in P&G's most commodity-exposed category, in the year its input costs are rising fastest.
Guidance & Outlook
| Metric | July guide | October guide | Change |
|---|---|---|---|
| Organic sales growth | +1% to +3% | +1% to +3% | Maintained |
| All-in net sales growth | +1% to +3% | +2% to +4% | Raised (Thorne) |
| Core EPS growth | 0% to +3% ($6.89 to $7.11) | 0% to +3% ($6.89 to $7.11) | Maintained |
| All-in diluted EPS growth | +1% to +5% | +1% to +5% | Maintained |
| Core effective tax rate | ~20% | 20% to 21% | Raised |
| Input cost headwind (after tax) | ~$1.0B at $90 Brent | ~$1.4B at $100 Brent | Raised $0.4B |
| Higher net interest (after tax) | ~$150M | ~$300M | Raised (acquisition debt) |
| Total headwind per share | $0.56 (8%) | $0.79 (11%) | Raised $0.23 |
| Free cash flow productivity | 85% to 90% | 85% to 90% | Maintained |
| Capital spending (% of sales) | 4.5% to 5.5% | 4.5% to 5.5% | Maintained |
| Dividends / repurchases | >$10B / ~$5B | >$10B / ~$5B | Maintained |
| First-half organic sales (verbal) | n/a | ~3% | New; implies Q2 near 2% |
The fiscal 2027 headwind, July vs. October
| Item (after tax) | July | October | Change |
|---|---|---|---|
| Raw materials, energy, transportation and premiums | ~$1,000M | ~$1,400M | +$400M |
| Higher net interest expense | ~$150M | ~$300M | +$150M |
| Lower non-operating income | ~$150M | ~$150M | unchanged |
| Unfavorable foreign exchange | ~$50M | ~$50M | unchanged |
| Total | ~$1,350M | ~$1,900M | +$550M |
| Per share / share of FY26 core EPS | $0.56 / 8% | $0.79 / 11% | +$0.23 / +3 pts |
The release frames the guidance change narrowly, as an all-in sales update for Thorne with everything else maintained. The call is where the substance sits: a guide that held while its cost assumptions rose by $0.23 a share, and a top-line cadence that points above the range.
Implied ramp: Q1 core EPS of $2.00 leaves $4.89 to $5.11 for the remaining nine months, against $4.90 in the same period of fiscal 2026 ($1.88, $1.59 and $1.43). That is growth of about 0% to 4%, or 2% at the midpoint, in the three quarters that carry most of the $0.79 headwind. The core tax-rate range moving to 20% to 21% from about 20% is worth roughly another four cents at the midpoint on our arithmetic. Management's productivity is weighted to the back half and any pricing is likely timed to second-half resets, so the December quarter is the trough for earnings growth.
Street at: Entering the print the Street sat near $6.97 of core EPS and 2.2% organic growth for fiscal 2027. The quarter argues for organic estimates moving toward 3%; the higher headwind and an oil price above the guide's assumption argue against EPS estimates moving at all.
Guidance style: Conservative and, unusually, asymmetric. P&G gave a verbal top-line cadence that sits at the top of its own range, declined to give the December-quarter EPS steer it volunteered for September, and declined to commit to the EPS midpoint. Its record of guiding low and landing inside the range held in every line of fiscal 2026. The risk this year is not credibility; it is that the cost assumption keeps chasing the oil market upward.
Analyst Q&A Highlights
Why margins look better at this level of volume growth than in fiscal 2022
The opening question compared the quarter with fiscal 2022, the last time P&G posted volume above 2% with 4% organic growth, and asked whether the better margin outcome this time is quarter-specific or a structural change in operating leverage. Management split the answer into three structural drivers (rising cost-of-goods productivity, the overhead reduction now flowing, and more effective brand spend) and two quarter-specific ones: a partial commodity flow-through and a roughly $90M tariff refund.
Q: "We had to go back a ways in our model to find the last time that P&G posted volumes up more than 2% and organic at 4%. But when we found that time, which is back in, I think, 22, optically, margins are up a lot more this time around."
— Lauren Lieberman, Barclays
A: "I think it is a combination of quarter specifics and structural. So let me start with the structural maybe. When we see growth around 4% and volume growth at or above 2%, we have always seen leverage. … The last point I will give you is we had the second part of the IEEPA tariff refund in quarter 1. Of about $90 million"
— Andre Schulten, CFO
Assessment: The most useful exchange on the call because it separated what will repeat from what will not. The overhead and productivity leverage should persist; the commodity timing and the refund will not. Investors annualizing Q1's 80 bps of operating-margin decline are using the wrong base.
Whether the December quarter was robbed to pay for September
A question on sustainability asked whether shipment timing or competitive factors flattered Q1 at Q2's expense. Management steered firmly to a first-half number of about 3% and a slight second-half acceleration, acknowledged some shipment timing around European promotional events, and described the company as roughly 60% of the way through fixing its category-country combinations.
Q: "We think about this first semester, the December quarter, were there any shipment timing, competitive factors, or other dynamics that may have materially flattered 1Q at the expense of 2Q in your mind?"
— Steve Powers, Deutsche Bank
A: "But I think the overarching headline that I want you to take away is 3% for H1, and slight acceleration in half 2, which means consistent value and volume share growth."
— Andre Schulten, CFO
Assessment: A direct answer to a direct question. Management chose to anchor expectations at 3% rather than let the 4% headline run, which is the right call and the strongest signal that it believes the underlying rate is real.
Why guide a deceleration into an easier comparison
The most persistent line of questioning in the session pressed on the implied December-quarter slowdown, given that comparisons ease in every segment except Health Care and management's own commentary was uniformly positive. The answer named the consumer as the swing variable: fuel prices, the US midterm elections and the Middle East, alongside the European pre-shipment.
Q: "Are there any real business reasons to expect such a deceleration into the second quarter versus the first quarter? Given everything that you have said about how the initiatives are working across the different divisions?"
— Multiple analysts incl. Kaumil Gajrawala (Jefferies), Chris Carey (Wells Fargo)
A: "The consumer is the key variable here. Look, we are looking at fuel prices, gas prices around the world. That are creating turmoil. … And so far, the consumer has held up. We do not know if that is gonna continue."
— Andre Schulten, CFO
Assessment: There is no operational reason given for the slowdown beyond a point of European timing, which makes the 3% first-half guide look like a hedge on the consumer rather than a forecast of weaker execution. That is the setup for a beat in the December quarter if the consumer holds, and it is how we read the guide.
How pricing will offset a $1.4 billion commodity bill
With the input-cost estimate up $400M and looking more durable, a question asked how management weighs pricing against a weak developed-market consumer, a promotional environment and retailer pushback. The answer laid out the three levers: record productivity from a project list described as complete, pricing with innovation, and time to recover the dollars without compromising momentum.
Q: "So just in light of how severe the commodity backdrop looks, how are you thinking about pricing as an offsetting lever to that cost pressure"
— Dara Mohsenian, Morgan Stanley
A: "We will price we will price with innovation. Not jeopardizing the top line momentum. The third component here is time."
— Andre Schulten, CFO
Assessment: "Time" is the honest word in that answer. Recovering $1.4B of after-tax cost through innovation-linked pricing takes multiple reset cycles, which means fiscal 2027 absorbs the cost and fiscal 2028 is when pricing catches up. That supports valuing the stock on fiscal 2028 rather than on a cost-trough fiscal 2027.
How the inflation lands quarter by quarter
Asked to unpack the phasing of an input-cost headwind that ran at 5% of earnings in Q1 against 8% for the year, management gave the clearest guidance of the session and then stopped. Q2 inventory was produced at $100 oil, so the full-year rate lands in Q2; oil at $113 means more in Q3 and Q4, where there is more time to react.
Q: "But as we think about productivity and pricing, are there any quarters where you would expect to see a greater gap between those offsets? Relative to the inflation, that could result in more outsized profit pressure."
— Peter Grom, UBS
A: "Q2 has been produced at $100 a barrel. So when I look at 8, reflecting $100 a barrel, my assumption if I were you would be that flows through in Q2. Oil at 113 means more is coming in Q3 and Q4. For Q3 and Q4, we have more time to react. For Q2, we have little. So I will leave it at that."
— Andre Schulten, CFO
Assessment: "I will leave it at that" is as close as P&G comes to a December-quarter EPS warning. With little time to react, an 8% input-cost drag and first-half organic guided to about 3%, the December quarter's core EPS is likely to decline year over year. The guide's second-half cost is understated at $113 oil, which is why we sit near the bottom of the EPS range.
Whether the EPS midpoint is still in reach
A follow-up asked whether, with organic tracking toward the top of the range, management remained confident in at least the midpoint of the EPS range. The answer was a polite decline.
Q: "But just like what is your confidence level still in at least achieving the midpoint range on EPS just given the elevated cost environment?"
— Peter Galbo, Bank of America
A: "Give us a bit of time to get our hands around the commodity impact, pricing plans, productivity, and that is why we are reiterating the range So I am confident in the range. But we will need time to figure out where that range will end up."
— Andre Schulten, CFO
Assessment: A company that beat its own quarterly steer by eleven cents and still will not commit to the midpoint is telling investors the costs ahead are larger than the beat. We take it at its word.
How much of China's 8% is a competitor's problem
A question on China asked how the business could grow so strongly against a weak macro backdrop. Management walked through the post-pandemic rebuild of distribution, social-first marketing and execution, then isolated the one-off: about 3 points of growth from trial driven by a competitor's disruption in diapers.
Q: "But the business is doing really well. So I just wanted to kind of understand exactly what is going on. Is this a beauty specific thing?"
— Nik Modi, RBC Capital Markets
A: "In Q1 now, it is growing almost 50%. that is obviously driven by the competitive issue that existed in the market, which is driving a ton of trial for Pampers. … So if you take that out, China would still be growing at 5% that it has been growing so mid single digits."
— Andre Schulten, CFO
Assessment: Volunteering the size of a windfall is the kind of disclosure that builds credibility. China ex the one-off is a steady mid-single-digit share gainer; the three points are a retention opportunity, not a run rate.
How Thorne fits, and who runs it
The only question on Thorne asked how P&G helps a business with aggressive growth objectives that it intends to run separately, and how it retains the people who built it. The answer committed to a light-touch model, with international expansion and later category extension as the levers, and deferred the detail to the Investor Day.
Q: "Thorn has some aggressive growth objectives over the next couple of years. To what extent does Procter help enable that I think the plan is to have it run separate from Proctor's operations"
— Robert Moskow, TD Securities
A: "Where do we add I think we can add in international expansion. Because this brand and the benefit space is relevant not only in The US, but way beyond The US."
— Andre Schulten, CFO
Assessment: The strategy is sensible and the disclosure is thin. Investors were given a price, a segment and an interest cost, and nothing on revenue, growth or margin. For a $3.9B all-cash deal, that is an omission the Investor Day needs to fill.
What They're NOT Saying
- The December-quarter EPS: in July management volunteered that Q1 core EPS would fall 5% or more. This quarter it said costs will be "materially higher" in Q2, that Q2 inventory was produced at $100 oil and that there is little time to react, and then declined to size the quarter. The steer it gave when the news was bad is missing now that the news is worse.
- A sensitivity to oil above $100: the guide assumes $100 Brent; management cited $110 to $113 on the day. No per-$10 sensitivity was offered, and the July-to-October revision ($90 to $100 added $400M after tax) is the only reference point investors have.
- Any gross-margin or operating-margin direction for fiscal 2027: now three consecutive quarters without one. With core gross margin down 150 bps on only part of the cost wave, this is the most important missing number in the model.
- The grew-versus-held split inside the 29 of 50: requested in July, still not disclosed. The improvement from 23 to 29 would read very differently if most of the gain is in "held."
- Whether pricing is in the guide: asked directly, management said it could not discuss future pricing and later that "everything we know" is in the outlook. Investors cannot tell whether second-half pricing is upside to the range or already inside it.
- Thorne's revenue, growth and margin: none given on the call; the 10-Q calls the business not material. The purchase price was $3.9B in the filing, and the after-tax interest it carries appears only as part of the $300M net interest line.
- The cost of the value corrections: pricing was negative in Fabric & Home Care (0.3 points) and Baby, Feminine & Family Care (1.2 points), and those two segments' gross margins fell 290 bps and 220 bps. No one asked how much of the volume recovery depends on price levels that the coming pricing actions would reverse.
- Any Tide Evo number: Evo was mentioned only as one of several examples "continued to deliver strong results," with no distribution, revenue or share figure, after several calls without one.
- Retention of the China diaper windfall: management sized the benefit at about 3 points of China growth but gave no view on how long the competitor's disruption lasts or what share of trial users have repeated.
Market Reaction
- Pre-print setup: PG closed at $156.84 on October 21, up 9.4% year to date, up 3.0% over the trailing twelve months and up 5.8% over the trailing 30 days. The 52-week closing range was $138.04 to $167.20, so the stock entered the print in the upper half of its range and about 4 points behind the S&P 500's 13.3% year-to-date gain. It had already risen 7.4% from the $146.10 close against which our July downgrade was priced.
- Reaction session (October 22, before the open): shares opened 3.4% higher at $162.14 in the opening auction, traded above $165 within five minutes, ranged between $161.36 and $166.85, and closed at $165.59, up 5.6% or $8.75.
- Volume: 22.0M shares against an 8.9M 30-day average, 2.5 times normal.
- Relative: the S&P 500 fell 1.2% the same session, so PG outperformed the index by about 6.8 points. The consumer-staples sector ETF rose 3.3%, and household peers rose 3.7% to 5.3%.
- Next session (October 23): PG fell 2.8% to $161.02 on 10.3M shares, as the S&P 500 fell 0.5% and the staples ETF gave back 1.9%. The two-session move was +2.7% against -1.7% for the index.
Two forces drove the session and they need to be separated. The first is the print: a volume-led beat with every category growing is exactly what a stock de-rated on growth concerns needs, and PG outperformed its own sector by about 2.3 points on the day. The second is rotation. The broad market fell, money moved from technology into defensives, and the large household-products names rose between 3.7% and 5.3%. The sector's 3.3% accounts for more than half of PG's 5.6% gain.
The next session's giveback, larger than both the index's decline and the staples sector's reversal, supports that split. Over the two sessions PG held about 1.3 points of outperformance against its sector, which is a reasonable price for a quarter that resolved the top-line question but raised the cost question.
What the move has done is close most of the gap between our prior fair value and a fully valued stock. At $161.02 PG trades at 23.0x the unchanged $7.00 FY27 midpoint, against 20.9x at our July downgrade: a re-rating of about two turns on an earnings guide that has not moved and a cost assumption that has risen. The re-rating is justified on the top line; it leaves little room for the December quarter.
Street Perspective
Debate: Is 4% the new run rate or another alternation?
Bull view: The breadth settles it. Every category, every region, volume-led, the US customer share metric above 70% and heading to 80%, categories accelerating to 2.5% to 3%, and comparisons easing in the December and June quarters. The first-half 3% guide is a hedge, and the full year lands above the top of the 1% to 3% range.
Bear view: The past five quarters ran +2%, 0%, +3%, 0% and +4%. Management itself guides the December quarter near 2% on an easy comparison, and the September quarter carried European pre-shipments, a China windfall and some North American restocking. Calling a trend on one quarter repeats the mistake made after the March quarter, when a 3% print was followed by 0%.
Our take: The bull side has the better argument this time, for a reason that is not in the headline: breadth and customer-level share are not distorted by timing, and both improved decisively. We accept 3% as the structural rate and expect the December print to land near 2% to 3%. The bear point that keeps us from going further is not the top line; it is costs.
Debate: Can productivity and pricing keep pace with a cost bill that keeps growing?
Bull view: The guide just absorbed a $0.23 increase without moving. Productivity is running at record levels, the overhead reduction is flowing, the industry is pricing, and P&G has a volume tailwind to price into. Cost spikes in staples are recovered with a lag, and fiscal 2028 gets the benefit.
Bear view: The cost estimate is 40% higher than in April at the same $100 oil assumption, and it still trails spot crude by $10 or more. The December quarter takes the full $100 cost with little time to react, management will not commit to the EPS midpoint, and pricing into a fragile volume recovery risks undoing the very value corrections that produced it.
Our take: The bears are right about fiscal 2027 and the bulls are probably right about fiscal 2028. We model fiscal 2027 core EPS of $6.92, near the bottom of the range, and fiscal 2028 of $7.55 as pricing and productivity catch up. The rating depends on how much of that recovery an investor is willing to pay for today.
Debate: Has the stock already priced the turn?
Bull view: A Dividend King returning to its long-term algorithm with volume growth deserves a premium staples multiple. At about 21x fiscal 2028 and a 2.7% yield, with an Investor Day less than four weeks away likely to set out a medium-term framework and the market rotating toward defensives, the stock can work from here.
Bear view: At 23x a fiscal 2027 guide of 0% to 3% earnings growth, with the cost assumption below spot oil and a 10-year Treasury yield near 5%, the stock is pricing the recovery before the earnings show it. Sell-side targets that jumped after the print are chasing a move that was more than half sector rotation.
Our take: Both are describing the same stock at fair value. The top-line evidence removes the reason for a below-market rating, and the cost picture plus the multiple remove the reason for an above-market one. That is a Hold.
Model Update Needed
| Item | Prior assumption (July) | Suggested change | Reason |
|---|---|---|---|
| FY27 organic growth | +1.5% to +2.0% | ~+3.0% | Q1 4.0%; first half guided ~3% and second half slightly higher; categories at 2.5% to 3% |
| FY27 all-in net sales growth | ~+1.5% to +2.0% | ~+4% | Organic ~3% plus roughly a point from Thorne from Q2 |
| FY27 core gross margin | (30) to (60) bps | (150) to (200) bps | Q1 (150) bps on a 5% input-cost headwind; full year 8% at $100 Brent, more at spot |
| FY27 core operating margin | (50) to (100) bps | (80) to (120) bps | Overhead leverage partly offsets the steeper gross-margin decline |
| FY27 headwind (per share) | $0.56 | $0.79, risk higher | Company estimate at $100 Brent; spot $110 to $113 |
| FY27 core EPS | $6.90 to $7.00 (base ~$6.95) | $6.89 to $7.00 (base $6.92) | Q1 beat largely timing; $0.23 higher headwind offset by stronger volume and second-half pricing |
| Q2 FY27 core EPS | n/a | Down year over year | Full $100 oil cost lands in Q2 with "little" time to react |
| FY28 core EPS | $7.35 to $7.60 | $7.45 to $7.65 (base $7.55) | Organic ~3%, pricing annualizes, productivity continues, interest steady; +9% on the FY27 base |
| Capital return | ~$15B | ~$15B | Reaffirmed; Thorne funded with debt |
| Net debt | $24.2B (June 30) | ~$27.5B pro forma | $23.6B at September 30 plus the $3.9B paid on October 1 (derived) |
Valuation impact: We raise fair value to $155 to $170 from $132 to $148, and move the anchor from fiscal 2027 to fiscal 2028. The band is 20.5x to 22.5x our fiscal 2028 base of $7.55. We make the switch now because fiscal 2027 carries an 11% exogenous cost drag that management expects to recover through pricing over time, and this quarter's top-line evidence is what makes that recovery credible; in July, without it, we declined to give the trough argument credit. For continuity, the new band is 22.1x to 24.3x the $7.00 FY27 midpoint, against 19.0x to 21.0x in July, and our July band equates to about 17.7x to 19.8x the midpoint of our July fiscal 2028 range. The re-rating of our own band reflects the removal of the decelerating-growth discount, not a change in method. The midpoint of $162.50 is about 1% above the $161.02 close; with the 2.7% dividend yield, that is an expected total return of roughly 3% to 4%. That sits at the low end of what we would call in line with the market, and with a 10-year Treasury yield near 5% we are not willing to pay a higher multiple for a bond-like staple. We accept it at Hold because the top-line risk that justified a below-market call has fallen; it is also why the rating goes no further.
Thesis Scorecard Post-Earnings
July commitments, graded
| What we said to watch in July | Outcome | Notes |
|---|---|---|
| Q1 core EPS at or above ~$1.89 | Delivered | $2.00, up 1%, against a "down 5% or more" steer |
| North American organic turning positive | Delivered | +3% on 3 points of volume |
| Top-50 share metric improving off 23; grew-vs-held split | Partly | 29 fiscal year to date; split still undisclosed |
| Any FY27 gross or operating margin direction | Not given | Third consecutive quarter without one |
| A dollar figure for FY27 productivity | Partly | About $500M to $550M before tax in Q1; "similar" to FY26's $2.8B |
| Volume/price/mix composition | Delivered for Q1 | 2.4 / 0.4 / 1.1, volume-led; no forward split |
| Family Care returning to growth | Partly | Organic up low single digits; North American share down 0.5 points |
| Any Tide Evo number | Not given | Mentioned only as an example |
| Brent below $90 producing a guidance benefit | Reversed | Assumption raised to $100; headwind up $0.4B after tax |
| Investor Day and portfolio action | Pending | November 19 confirmed; Thorne bought for $3.9B, no divestment discussed |
| Thesis Point | Status | Notes |
|---|---|---|
| Bull #1: Operational reacceleration | Confirmed | Organic 4.0% on 2.4 points of volume, 10 of 10 categories and 6 of 6 regions growing, North America +3%. Management guides the first half to about 3%, a point above the second-half fiscal 2026 structural rate. Status: AT RISK → ON TRACK. |
| Bull #2: Productivity and restructuring self-fund reinvestment | Confirmed | 250 bps of gross productivity; SG&A dollars flat with overhead down 70 bps of sales; the 15% non-manufacturing headcount reduction now flowing; productivity on a pace similar to FY26's $2.8B. Status: ON TRACK. |
| Bull #3: Capital-return durability and defensive quality | Confirmed | $3.9B returned in the quarter, 93% free cash flow productivity, ~$15B FY27 plan reaffirmed, dividend up 3.0% year over year. Thorne adds about $3.9B of debt-funded leverage. Status: ON TRACK. |
| Bear #1: Organic growth stall and US share loss | Challenged | 29 of top 50 combinations holding or growing share, from 23 in Q4; over 70% of top US customers holding or growing share; global aggregate share flat. Share still down in Skin Care, Oral Care, Personal Care and North American Family Care. Status: EMERGING → CONTAINED. |
| Bear #2: Margin and cost pressure, including the oil shock | Confirmed / escalating | Headwind raised to $0.79 a share (11%) from $0.56 (8%) at $100 Brent, with spot $110 to $113; core gross margin down 150 bps on only part of the wave; December quarter carries the full cost. Status: MATERIALIZING (unchanged). |
Overall: The thesis strengthened on the side that drove our downgrade and weakened on the side we already rated as materializing. The bull pillar we cut to AT RISK in July is back ON TRACK, and the US share bear point we escalated is back to CONTAINED, both a quarter or two earlier than we expected. The cost bear point is larger than it was in July and is still rising with oil. Net, the thesis has moved from one-sided to balanced.
Action: Upgrading to Hold from Underperform, with fair value raised to $155 to $170 against a $161.02 close. Our July note named the evidence that would bring us back to Hold, 2%+ organic with the share metric improving, and the September quarter delivered both decisively. We stop at Hold because the stock has re-rated by about two turns on an unchanged earnings guide, the December quarter will carry the full cost of $100 oil with spot above it, and management would not commit to its own EPS midpoint. We would move to Outperform on a pullback toward $145 to $150 with the volume trend intact, or on an Investor Day framework that credibly restores mid-single-digit EPS growth from fiscal 2028. We would return to Underperform if December-quarter organic falls below 2% or the EPS range moves lower on oil.